Dual-time point scanning of integrated FDG PET/CT for the evaluation of mediastinal and hilar lymph nodes in non-small cell lung cancer diagnosed as operable by contrast-enhanced CT

European Journal of Radiology

Volumn 75, Issue 2, 2010, Pages 143-146

  Kasai, Takami ^a   Motoori, Ken ^a   Horikoshi, Takuro ^a   Uchiyam, Katsuhiro ^c   Yasufuku, Kazuhiro ^b   Takiguchi, Yuichi ^b   Takahashi, Fumiaki ^d   Kuniyasu, Yoshio ^c   Ito, Hisao ^a  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Sannoh Medical Center   (Japan)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

Dual time point scanning; Integrated FDG PET CT; Lymph node metastasis; Non small cell lung cancer

Indexed keywords

BIOLOGICAL ORGANS; BODY FLUIDS; CELLS; CYTOLOGY; DISEASES; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; REGRESSION ANALYSIS; SCANNING;

AREA UNDER THE ROC CURVE; DUAL TIME; FDG PET; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; NON SMALL CELL LUNG CANCER; RECEIVER OPERATING CHARACTERISTICS; STANDARDIZED UPTAKE VALUES;

COMPUTERIZED TOMOGRAPHY;

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; DUAL TIME POINT SCANNING; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TIME;

EID: 77955850319     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.04.044     Document Type: Article

References (18)

1. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:319-23.
2. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: Report of the Radiologic Diagnostic Oncology Group. Radiology 1991;178:705-13.
3. Tahara RW, Lackner RP, Graver LM. Is there a role for routine mediastinoscopy in patients with peripheral T1 lung cancers? Am J Surg 2000;180:488-92.
4. Yasufuku K, Nakajima T, Motoori K, et al. Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. Chest 2006;130:710-8.
5. Duhaylongsod FG, Lowe VJ, Patz Jr EF, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130-9.
6. Lardinois D,WeberW, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Eng J Med 2003;348:2500-7. (Pubitemid 36706537)
7. Kang WJ, Chung JK, So Y, Jeong JM, Lee DS, Lee MC. Differentiation ofmediastinal FDGuptake observed in patientswith non-thoracic tumours. Eur JNuclMedMol Imaging 2004;31:202-7.
8. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in nonsmall- cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16(6):2142-9.
9. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-5.
10. Demura Y, Tsuchida T, Ishizaki T, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003;44:540-8.
11. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718-23.
12. Xiu Y, Bhutani C, Dhurairaj T, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007;32(2):101-5.
13. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose. J Nucl Med 1978;19:1154-61.
14. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001;28:696-703.
15. Dobert N, Hamscho N, Menzel C, Neuss L, Kovacs AF, Grunwald F. Limitations of dual time point FDG-PET imaging in the evaluation of focal abdominal lesions. Nuklearmedizin 2004;43:143-9.
16. Yen TC, Chang YC, Chan SC, et al. Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging 2005;32(5):541-8.
17. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999;26:1345-8.
18. Nakamoto Y, Higashi T, Sakahara H, et al. Delayed 18F-fluoro-2-deoxy-d- glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-54.